CiVi Biopharma ApS: Financial statements 2023
CVR: 38027794
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
CiVi Biopharma ApS (CVR 38027794) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 3,502,137 and a net result of DKK -1,887,334 compared with DKK 326,318 the year before. That is a decrease of 0.8% compared with the year before. Equity in the 2023 report amounted to DKK 1,488,019. The solvency ratio was 65.1%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 3,502,137
- Profit/Loss
- DKK -1,887,334
- Equity
- DKK 1,488,019
- Total Assets
- DKK 2,285,127
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 3.5M | -1.9M | 1.5M | 1 |
| 2022 | - | 3.5M | 326K | 3.4M | 1 |
| 2021 | - | 4M | 344K | 3M | 1 |
| 2020 | - | 4.5M | 392K | 2.7M | 1 |
| 2019 | - | 7.2M | 649K | 2.3M | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
CiVi Biopharma ApS has published its annual report for 2022. Gross profit came to DKK 3,530,115, and the net result was DKK 326,318.
About CiVi Biopharma ApS
CiVi Biopharma ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company has been dissolved on 5 February 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CiVi Biopharma A/S. The company has 1 employee (2024). In 2024, the company reported a gross profit of DKK 610,531 and a net result of DKK -1,410,204 compared with DKK -1,887,334 the year before. Equity in the 2024 report amounted to DKK 77,815.